Recent Advances in Therapeutic Targets of Tardive Dyskinesia
Keywords:
Tardive dyskinesia, Schizophrenia, DA-R super sensitivity, vacuous chewing movements, Neurotoxicity, ExcitotoxicityAbstract
Tardive dyskinesia is a hyperkinetic neurodegenerative movement disorder which is severe, debilitate, unrealized and everlasting mainly arises after prolong medication with Dopamine antagonist. The pathophysiology mechanisms of TD mainly consist of dopamine receptor super sensitivity, GABA depletion, cholinergic deficiency, neurotoxicity, changes in synaptic plasticity, and defective neuroadaptive signaling. Tardive dyskinesia is a progressive and potentially irreversible condition which mainly correlates to adverse of dopamine antagonism leading to neurodegeneration and movement disorders like Pill rolling movements of fingers, lip puckering, facial grimacing. Their recurrent factors could allow classify tardive dyskinesia according to their potential, beneficial targets so that it may be used for further initial interventions which are necessary. The focus of this article is a pathophysiology of and an understanding the complex cascade of secondary neurodegeneration.
Downloads
References
Skidmore, F.; Weiner, W. J.; Burke, R., Neuroleptic-induced tardive dyskinesia variants. In Drug-induced movement disorders, Futura publishing company, New York: 2005; pp 257-285.
Owens, D. C., A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge University Press: 2014.
Ozdemir, V.; Aklillu, E.; Mee, S.; Bertilsson, L.; Albers, L. J.; Graham, J. E.; Caligiuri, M.; Lohr, J. B.; Reist, C., Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert opinion on pharmacotherapy 2006,7 (2), 119-133.
Aguglia, E.; Lio, F. M. S.; Crisafulli, G., Discinesia tardiva: epidemiologia clinica, fattori di rischio e gestione terapeutica. Quaderni Italiani di Psichiatria 2011,30 (2), 65-74.
Jeste, D. V.; Wyatt, R. J., Understanding and treating tardive dyskinesia. Guilford Press: 1982.
Schonecker, M., Ein eigentumliches syndrom im oralen bereich bei megaphen applikation. Nervenarzt 1957,28 (35), 22.
Sigwald, J.; Bouttier, D.; Raymondeaud, C.; Piot, C., Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a evolution prolongee secondaire a un traitement par les neuroleptiques. Rev. neurol 1959,100, 751-755.
Wolf, M.; Yassa, R.; Llorca, P., Neuroleptic-induced movement disorders: historical perspectives. L'Encephale 1992,19 (6), 657-661.
Friedman, J. H., Historical perspective on movement disorders. Journal of Clinical Psychiatry 2004.
Lerner, V.; Miodownik, C., Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment. Current psychiatry reports 2011,13 (4), 295-304.
(a) De Leon, M. L.; Jankovic, J., Clinical features and management of classic tardive dyskinesia, tardive myoclonus, tardive tremor, and tardive tourettism. NEUROLOGICAL DISEASE AND THERAPY 2004,62, 77-110;(b) Lauterbach, E. C.; Carter, W. G.; Rathke, K. M.; Thomas, B. H.; Shillcutt, S. D.; Vogel, R. L.; Moore, N. C.; Mimbs, J. W.; Nelson, W. H., Tardive dyskinesia--diagnostic issues, subsyndromes, and concurrent movement disorders: a study of state hospital inpatients referred to a movement disorder consultation service. Schizophrenia bulletin 2001,27 (4), 601;(c) Fahn, S.; Jankovic, J., Parkinsonism-plus syndromes and secondary parkinsonian disorders. Principles and practice of movement disorders. Philadelphia: Churchill Livingstone Elsevier 2007, 233-84.
(a) Van Harten, P.; Matroos, G.; Van Os, J., The course of tardive dystonia in Afro Caribbean patients, a population-based study: the Curacao extrapyramidal syndromes study: VII. Schizophrenia research 2008,98 (1), 79-83;(b) Kilic, A.; Erten, E.; Ozdemir, A., Tardive blepharospasm and meige syndrome during treatment with quetiapine and olanzapine. Archives of Neuropsychiatry 2015,52 (2), 207-210.
Wong, D. F.; Braši?, J. R.; Singer, H. S.; Schretlen, D. J.; Kuwabara, H.; Zhou, Y.; Nandi, A.; Maris, M. A.; Alexander, M.; Ye, W., Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 2008,33 (6), 1239-1251.
Alam, S. A.; Baruah, A.; Agarwal, G.; Mohite, N., OJPAS™.
Tarsy, D.; Indorf, G., Tardive tremor due to metoclopramide. Movement disorders 2002,17 (3), 620-621.
Kuo, S., Metoclopramide/prochlorperazine/trifluoperazine. Reactions 2008,1197, 12.
Ilahi, M.; Shenker, D., THEORETICAL IMPLICATIONS OF THE USE OF L?DOPA IN PARKINSONISM. Acta neurologica scandinavica 1970,46 (4?5), 409-441.
Jeste, D. V.; Lohr, J. B.; Clark, K.; Wyatt, R. J., Pharmacological treatments of tardive dyskinesia in the 1980s. Journal of clinical psychopharmacology 1988,8 (4), 49S.
Tarsy, D., Interactions between acetylcholine and dopamine in the basal ganglia. In Brain Acetylcholine and Neuropsychiatric Disease, Springer: 1979; pp 395-424.
LIST, C.; FILE, P. E. S., Heon-Jeong Lee, MD, PhD.
Casey, D. E.; Gerlach, J.; Magelund, G.; Christensen, T. R., ?-Acetylenic GABA in tardive dyskinesia. Archives of General Psychiatry 1980,37 (12), 1376-1379.
Andreassen, O. A.; Jørgensen, H. A., Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats: implications for tardive dyskinesia? Progress in neurobiology 2000,61 (5), 525-541.
Klawans, H.; Rubovits, R., An experimental model of tardive dyskinesia. Journal of neural transmission 1972,33 (3), 235-246.
(a) Rana, A. Q.; Chaudry, Z. M.; Blanchet, P. J., New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther 2013,7 (6), 1329-1340;(b) Lieberman, J.; Kane, J.; Alvir, J., Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987,91 (4), 415-433.
(a) Lieberman, J.; Jody, D.; Geisler, S.; Alvir, J.; Loebel, A.; Szymanski, S.; Woerner, M.; Borenstein, M., Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of general psychiatry 1993,50 (5), 369-376;(b) Seeman, P., All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS neuroscience & therapeutics 2011,17 (2), 118-132.
Howes, O. D.; Kapur, S., The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophrenia bulletin 2009,35 (3), 549-562.
Delay, J.; Deniker, P.; Harl, J. In Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP), Annales medico-psychologiques, 1952; pp 112-117.
Carlsson, A.; Lindqvist, M., Effect of chlorpromazine or haloperidol on formation of 3?methoxytyramine and normetanephrine in mouse brain. Basic & Clinical Pharmacology & Toxicology 1963,20 (2), 140-144.
(a) Carlsson, A.; Lindqvist, M.; Magnusson, T., 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. 1957;(b) Seeman, P.; Lee, T., Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975,188 (4194), 1217-1219;(c) Creese, I.; Burt, D. R.; Snyder, S. H., Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976,192 (4238), 481-483;(d) Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K., Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976,261 (5562), 717-719.
Meador-Woodruff, J. H.; Haroutunian, V.; Powchik, P.; Davidson, M.; Davis, K. L.; Watson, S. J., Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex: focal abnormalities in orbitofrontal cortex in schizophrenia. Archives of general psychiatry 1997,54 (12), 1089-1095.
Davis, K. L.; Kahn, R. S., Dopamine in schizophrenia: a review and reconceptualization. The American journal of psychiatry 1991,148 (11), 1474.
(a) Suzuki, M.; Zhou, S.-Y.; Hagino, H.; Niu, L.; Takahashi, T.; Kawasaki, Y.; Matsui, M.; Seto, H.; Ono, T.; Kurachi, M., Morphological brain changes associated with Schneider's first-rank symptoms in schizophrenia: an MRI study. Psychological medicine 2005,35 (04), 549-560;(b) Lui, S.; Deng, W.; Huang, X.; Jiang, L.; Ma, X.; Chen, H.; Zhang, T.; Li, X.; Li, D.; Zou, L., Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study. American Journal of Psychiatry 2009,166 (2), 196-205.
Lieberman, J. A., Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biological psychiatry 1999,46 (6), 729-739.
(a) Benes, F. M.; Sorensen, I.; Bird, E. D., Reduced neuronal size in posterior hippocampus of schizophrenic patients. Schizophrenia bulletin 1991,17 (4), 597;(b) Browning, M. D.; Dudek, E. M.; Rapier, J. L.; Leonard, S.; Freedman, R., Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biological psychiatry 1993,34 (8), 529-535;(c) Daviss, S. R.; Lewis, D. A., Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons. Psychiatry research 1995,59 (1), 81-96;(d) Selemon, L. D.; Rajkowska, G.; Goldman-Rakic, P. S., Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Archives of general psychiatry 1995,52 (10), 805-818;(e) Arnold, S. E.; Franz, B. R.; Trojanowski, J. Q.; Moberg, P. J.; Gur, R. E., Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia. Acta neuropathologica 1996,91 (3), 269-277;(f) Perrone-Bizzozero, N. I.; Sower, A. C.; Bird, E. D.; Benowitz, L. I.; Ivins, K. J.; Neve, R. L., Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proceedings of the National Academy of Sciences 1996,93 (24), 14182-14187;(g) Glantz, L. A.; Lewis, D. A., Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: regional and diagnostic specificity. Archives of general psychiatry 1997,54 (10), 943-952;(h) Goldman-Rakic, P. S.; Selemon, L. D., Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophrenia bulletin 1997,23 (3), 437-458;(i) Zaidel, D. W.; Esiri, M.; Harrison, P., The hippocampus in schizophrenia: lateralized increase in neuronal density and altered cytoarchitectural asymmetry. Psychological medicine 1997,27 (03), 703-713;(j) Rajkowska, G.; Selemon, L. D.; Goldman-Rakic, P. S., Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Archives of General Psychiatry 1998,55 (3), 215-224.
(a) Rudnick, G.; Clark, J., From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochimica et Biophysica Acta (BBA)-Bioenergetics 1993,1144 (3), 249-263;(b) Eiden, L. E.; Weihe, E., VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Annals of the New York Academy of Sciences 2011,1216 (1), 86-98.
Fleckenstein, A. E.; Volz, T. J.; Riddle, E. L.; Gibb, J. W.; Hanson, G. R., New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 2007,47, 681-698.
Wilson, J. M.; Kalasinsky, K. S.; Levey, A. I.; Bergeron, C.; Reiber, G.; Anthony, R. M.; Schmunk, G. A.; Shannak, K.; Haycock, J. W.; Kish, S. J., Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature medicine 1996,2 (6), 699-703.
Sulzer, D.; Rayport, S., Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 1990,5 (6), 797-808.
Riddle, E. L.; Fleckenstein, A. E.; Hanson, G. R., Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. The AAPS journal 2006,8 (2), E413-E418.
(a) Laruelle, M.; Abi-Dargham, A.; van Dyck, C. H.; Rosenblatt, W.; Zea-Ponce, Y.; Zoghbi, S. S.; Baldwin, R. M.; Charney, D. S.; Hoffer, P. B.; King, H. F., Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release. Schizophrenia Research 1995,15 (1), 89-90;(b) Moszczynska, A.; Fitzmaurice, P.; Ang, L.; Kalasinsky, K. S.; Schmunk, G. A.; Peretti, F. J.; Aiken, S. S.; Wickham, D. J.; Kish, S. J., Why is parkinsonism not a feature of human methamphetamine users? Brain 2004,127 (2), 363-370.
Fitzmaurice, P. S.; Tong, J.; Yazdanpanah, M.; Liu, P. P.; Kalasinsky, K. S.; Kish, S. J., Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. Journal of Pharmacology and Experimental Therapeutics 2006,319 (2), 703-709.
Davidson, C.; Gow, A. J.; Lee, T. H.; Ellinwood, E. H., Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Research Reviews 2001,36 (1), 1-22.
Hirrlinger, J.; Schulz, J. B.; Dringen, R., Effects of dopamine on the glutathione metabolism of cultured astroglial cells: implications for Parkinson's disease. Journal of neurochemistry 2002,82 (3), 458-467.
Grima, G.; Benz, B.; Parpura, V.; Cuénod, M.; Do, K. Q., Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophrenia research 2003,62 (3), 213-224.
Jakel, R. J.; Kern, J. T.; Johnson, D. A.; Johnson, J. A., Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro. Toxicological Sciences 2005,87 (1), 176-186.
Shih, A. Y.; Erb, H.; Murphy, T. H., Dopamine activates Nrf2?regulated neuroprotective pathways in astrocytes and meningeal cells. Journal of neurochemistry 2007,101 (1), 109-119.
Hastings, T. G.; Lewis, D. A.; Zigmond, M. J., Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proceedings of the National Academy of Sciences 1996,93 (5), 1956-1961.
Schintu, N.; Frau, L.; Ibba, M.; Caboni, P.; Garau, A.; Carboni, E.; Carta, A. R., PPAR?gamma?mediated neuroprotection in a chronic mouse model of Parkinson’s disease. European Journal of Neuroscience 2009,29 (5), 954-963.
Chaturvedi, R. K.; Beal, M. F., PPAR: a therapeutic target in Parkinson’s disease. Journal of neurochemistry 2008,106 (2), 506-518.
Lastres-Becker, I.; Molina-Holgado, F.; Ramos, J. A.; Mechoulam, R.; Fernández-Ruiz, J., Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiology of disease 2005,19 (1), 96-107.
(a) Stokes, A. H.; Hastings, T. G.; Vrana, K. E., Cytotoxic and genotoxic potential of dopamine. Journal of neuroscience research 1999,55 (6), 659-665;(b) Sulzer, D.; Zecca, L., Intraneuronal dopamine-quinone synthesis: a review. Neurotoxicity research 1999,1 (3), 181-195.
Graham, D. G., Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Molecular pharmacology 1978,14 (4), 633-643.
Maker, H. S.; Weiss, C.; Silides, D. J.; Cohen, G., Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. Journal of neurochemistry 1981,36 (2), 589-593.
Nappi, A. J.; Vass, E.; Prota, G.; Memoli, S., The Effects of Hydroxyl Radical Attack on Dopa, Dopamine, 6?Hydroxydopa, and 6?Hydroxydopamine. Pigment Cell & Melanoma Research 1995,8 (6), 283-293.
Ehrenpreis, E.; Krishnan, A.; Alexoff, A.; Smith, D.; Wilensky, S., A Survey of Lawsuits Filed for the Complaint of Tardive Dyskinesia Following Treatment with Metoclopramide. Clin Pharmacol Biopharm 2015,4 (131), 2.
Acuña?Castroviejo, D.; Martin, M.; Macías, M.; Escames, G.; León, J.; Khaldy, H.; Reiter, R. J., Melatonin, mitochondria, and cellular bioenergetics. Journal of pineal research 2001,30 (2), 65-74.
Lohr, J. B.; Kuczenski, R.; Niculescu, A. B., Oxidative mechanisms and tardive dyskinesia. CNS drugs 2003,17 (1), 47-62.
Fridovich, I., The trail to superoxide dismutase. Protein Science 1998,7 (12), 2688-2690.
Robinson, B., The role of manganese superoxide dismutase in health and disease. Journal of inherited metabolic disease 1998,21 (5), 598-603.
(a) Sandyk, R.; Bamford, C. R.; Khan, I.; Fisher, H., L-trypiophan in neuroleptic-induced tardive dyskinesia. International journal of neuroscience 1988,42 (1-2), 127-130;(b) Spohn, H. E.; Coyne, L.; Spray, J., The effect of neuroleptics and tardive dyskinesia on smooth-pursuit eye movement in chronic schizophrenics. Archives of General Psychiatry 1988,45 (9), 833-840.
Lublin, H.; Gerlach, J., Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol. European journal of pharmacology 1988,153 (2-3), 239-245.
Glazer, W. M.; Morgenstern, H., Predictors of occurrence, severity, and course of tardive dyskinesia in an outpatient population. Journal of clinical psychopharmacology 1988,8 (4), 17S.
Liu, J., The effects and mechanisms of mitochondrial nutrient ?-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochemical research 2008,33 (1), 194-203.
(a) Beal, M. F., Aging, energy, and oxidative stress in neurodegenerative diseases. Annals of neurology 1995,38 (3), 357-366;(b) Simpson, G. M.; Yadalam, K. G.; Stephanos, M. J., Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia. Journal of clinical psychopharmacology 1988,8 (4), 52S.
Lohr, J. B., Oxygen radicals and neuropsychiatric illness: some speculations. Archives of General Psychiatry 1991,48 (12), 1097-1106.
Weiner, W. J.; Nausieda, P. A.; Klawans, H. L., Effect of chlorpromazine on central nervous system concentrations of manganese, iron, and copper. Life sciences 1977,20 (7), 1181-1185.
Jenner, P., Oxidative damage in neurodegenerative disease. The Lancet 1994,344 (8925), 796-798.
Behl, C.; Rupprecht, R.; Skutella, T.; Holsboer, F., Haloperidol-induced cell death-mechanism and protection with vitamin E in vitro. Neuroreport 1995,7 (1), 360-364.
Galili-Mosberg, R.; Gil-Ad, I.; Weizman, A.; Melamed, E.; Offen, D., Haloperidol–induced neurotoxicity–possible implications for tardive dyskinesia. Journal of neural transmission 2000,107 (4), 479-490.
(a) Post, A.; Holsboer, F.; Behl, C., Induction of NF-?B activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-?B and neuroprotection by antioxidants. Journal of Neuroscience 1998,18 (20), 8236-8246;(b) Sagara, Y., Induction of reactive oxygen species in neurons by haloperidol. Journal of neurochemistry 1998,71 (3), 1002-1012.
Calabresi, P.; Stefani, A.; Mercuri, N. B.; Bernardi, G., Acetylcholine-dopamine balance in striatum: Is it still a target for antiparkinsonian therapy? In Central Cholinergic Synaptic Transmission, Springer: 1989; pp 315-321.
Cragg, S. J., Meaningful silences: how dopamine listens to the ACh pause. Trends in neurosciences 2006,29 (3), 125-131.
Ding, J.; Guzman, J. N.; Tkatch, T.; Chen, S.; Goldberg, J. A.; Ebert, P. J.; Levitt, P.; Wilson, C. J.; Hamm, H. E.; Surmeier, D. J., RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nature neuroscience 2006,9 (6), 832-842.
(a) Pisani, A.; Bernardi, G.; Ding, J.; Surmeier, D. J., Re-emergence of striatal cholinergic interneurons in movement disorders. Trends in neurosciences 2007,30 (10), 545-553;(b) Aosaki, T.; Miura, M.; Suzuki, T.; Nishimura, K.; Masuda, M., Acetylcholine–dopamine balance hypothesis in the striatum: An update. Geriatrics & gerontology international 2010,10 (s1), S148-S157.
(a) Corner, B., Dystonia musculorum deformans in siblings; treated with artane (trihexyphenidyl). Proceedings of the Royal Society of Medicine 1952,45 (7), 451-452;(b) Lang, A.; Sheehy, M.; Marsden, C., Acute anticholinergic action in focal dystonia. Advances in neurology 1982,37, 193-200;(c) Sanberg, P. R.; Shytle, R. D.; Silver, A. A., Treatment of Tourette's syndrome with mecamylamine. The Lancet 1998,352 (9129), 705-706;(d) Brocks, D. R., Anticholinergic drugs used in Parkinson’s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci 1999,2 (2), 39-46;(e) SILVER, A. A.; SHYTLE, R. D.; SANBERG, P. R., Mecamylamine in Tourette's syndrome: a two-year retrospective case study. Journal of child and adolescent psychopharmacology 2000,10 (2), 59-68.
Everitt, B. J.; Robbins, T. W., Central cholinergic systems and cognition. Annual review of psychology 1997,48 (1), 649-684.
(a) Bertorelli, R.; Consolo, S., D1 and D2 dopaminergic regulation of acetylcholine release from striata of freely moving rats. Journal of neurochemistry 1990,54 (6), 2145-2148;(b) DeBoer, P.; Heeringa, M. J.; Abercrombie, E. D., Spontaneous release of acetylcholine in striatum is preferentially regulated by inhibitory dopamine D 2 receptors. European journal of pharmacology 1996,317 (2), 257-262;(c) Yan, Z.; Song, W.-J.; Surmeier, D. J., D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. Journal of Neurophysiology 1997,77 (2), 1003-1015.
(a) Giorguieff, M.; Le Floc'h, M.; Westfall, T.; Glowinski, J.; Besson, M., Nicotinic effect of acetylcholine on the release of newly synthesized [3 H] dopamine in rat striatal slices and cat caudate nucleus. Brain research 1976,106 (1), 117-131;(b) Chesselet, M.-F., Presynaptic regulation of neurotransmitter release in the brain: facts and hypothesis. Neuroscience 1984,12 (2), 347-375;(c) Rapier, C.; Lunt, G. G.; Wonnacott, S., Stereoselective Nicotine?Induced Release of Dopamine from Striatal Synaptosomes: Concentration Dependence and Repetitive Stimulation. Journal of neurochemistry 1988,50 (4), 1123-1130.
(a) Albin, R. L.; Young, A. B.; Penney, J. B., The functional anatomy of basal ganglia disorders. Trends in neurosciences 1989,12 (10), 366-375;(b) Crossman, A., A hypothesis on the pathophysiological mechanisms that underlie levodopa?or dopamine agonist?induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Movement Disorders 1990,5 (2), 100-108;(c) DeLong, M. R., Primate models of movement disorders of basal ganglia origin. Trends in neurosciences 1990,13 (7), 281-285.
Egan, M. F.; Hurd, Y.; Hyde, T. M.; Weinberger, D. R.; Wyatt, R. J.; Kleinman, J. E., Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic?induced dyskinesias. Synapse 1994,18 (3), 178-189.
Hyde, T. M.; Hotson, J. R.; Kleinman, J. E., Differential diagnosis of choreiform tardive dyskinesia. The Journal of neuropsychiatry and clinical neurosciences 1991.
(a) Jeste, D. V.; Wyatt, R. J., In search of treatment for tardive dyskinesia: review of the literature. Schizophrenia Bulletin 1979,5 (2), 251-293;(b) Jeste, D. V.; Wyatt, R. J., Therapeutic strategies against tardive dyskinesia: two decades of experience. Archives of General Psychiatry 1982,39 (7), 803-816.
Thaker, G. K.; Tamminga, C. A.; Alphs, L. D.; Lafferman, J.; Ferraro, T. N.; Hare, T. A., Brain ?-aminobutyric acid abnormality in tardive dyskinesia: reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Archives of general psychiatry 1987,44 (6), 522-529.
Stahl, S. M.; Thornton, J. E.; Simpson, M. L.; Berger, P. A.; Napoliello, M. J., Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biological psychiatry 1985,20 (8), 888-893.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
